Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma

Abstract

The combination of gemcitabine plus pegylated liposomal doxorubicin was active and safe in advanced HCC. Moreover, this treatment induced some complete responses and converted some untreatable HCCs into lesions eligible for resection or transplantation.